Meet the team that is driving our mission to discover insights that cure disease and heal healthcare
Colin Hill is a leading voice in healthcare technology and precision medicine and brings impressive leadership experience in commercializing machine learning technologies in the biopharmaceutical and managed care industries. He co-founded GNS Healthcare, a leading AI-driven precision medicine company, in 2000 and has since served as Chairman & CEO. In 2020 the company launched the in silico patient, a highly accurate computer model of disease.
Colin sits on board of Biotelemetry Inc. (NASDAQ: BEAT), the leading mobile health information company, and PPD, a leading global contract research organization. He is also a founding board member of TMed (Transforming Medicine: The Elizabeth Kauffman Institute), a non-profit foundation (501c3) dedicated to the advancement of personalized medicine. In 2016, he was appointed by Massachusetts Governor Charlie Baker to the Massachusetts Digital Health Council.
Colin was a founding member of the Board of Directors of AesRx, a biopharmaceutical company dedicated to the development of new treatments for sickle cell disease (acquired by Baxter in 2014). He was the founding chairman of O’Reilly Media’s Strata Rx in 2012, the first healthcare big data conference in the industry. In 2004, Colin was named to MIT Technology Review’s TR100 list of the top 100 innovators in the world under the age of 35.
He is a frequent speaker at national and international scientific and industry conferences and has appeared in numerous publications and television programs, including The Wall Street Journal, CNBC Morning Call & SquawkBox, Nature, Boston Globe, Politico, Forbes, Wired, and The Economist.
He graduated from Virginia Tech with a degree in physics and earned Master’s degrees in physics from both McGill University and Cornell University.
Mark Pottle is responsible for the finance, accounting and legal functions of GNS Healthcare.
Before joining GNS Healthcare, Mark was CFO of N-of-One Therapeutics, which provides analysis and interpretation of a tumor’s genome so that providers can personalize cancer treatments for patients. Prior to N-of-One, Mark worked at Picis Inc., which provides EMRs for emergency departments, ICUs, and ORs. After Picis was sold to United Healthcare/Optum in 2010, Mark became the CFO of Optum’s Accountable Care Organization division. Mark has also previously worked at several start-up to mid-level companies and has helped raise over $50 million of venture-backed funding, as well as over $150 million in private equity funding.
Mark is also a veteran of the U.S. Army. He graduated from University of New Hampshire with a degree in economics and holds an MBA from Southern New Hampshire University.
VP People and Culture
Ken is responsible for the Human Resource function of GNS Healthcare.
Before joining GNS Healthcare, Ken was the Vice President of Human Resources for ORIG3N Inc, a Biotechnology company that specializes in DNA testing and regenerative medicine. Prior to ORIG3N Ken was the VP of HR for Skyword Inc., a company that developed proprietary software to enhance Content Marketing for its customers. He has worked at multiple start-up companies including CambridgeSoft that created an electronic notebook (ELN) for the Pharma Industry. Ken was part of the senior team that merged CambridgeSoft and 2 other companies into the PerkinElmer Informatics group where he led the HR function for the $150 million-dollar division. Ken has consulted to multiple software, biotech and technology companies over the years and was the VP of HR for an incubator that launched software security companies.
Ken graduated Bridgewater State University with a BS in Education.
VP Technology
Roberto Olivares is responsible for the Engineering, Product and IT/DevOps team at GNS. The Technology Team is in charge of building, developing and deploying REFS and its accompanying platforms like ModelExplorer
Prior to GNS, Roberto worked at a biotech startup as a Research Scientist working on providing novel bioinformatics algorithms. Prior to that, Roberto worked in quantum computational chemistry where he developed electronic structure methods. He was a founding member of Harvard’s Clean Energy Project, a large-scale computational screening and design for solar cell materials.
Roberto holds a Ph.D. in Chemical Physics from Harvard University followed by a Postdoctoral stint at Princeton University from 2012-2014.
SVP Business Development
Keith leads GNS’ business development team and is responsible for client initiatives within the pharmaceutical industry and his primary responsibilities focus on client relationships and communication of needs. Working to understand customer needs and challenges Keith ensures that the GNS teams provide solutions to support decisions making through discovery, development, and commercialization. Keith has experience in Business Development for over 17 years and in the pharmaceutical industry for 28 years. Prior to joining GNS, he worked at several technology companies focused on bringing innovative capabilities to the discovery and development of human therapeutics such as in-silico fragment based drug design and gene evolution protein engineering. He also spent the first 10 years at Merck & Co and EMD where he learned the pharmaceutical development process and managed several products from discovery through to product approval and launch. This experience has provided him with a broad level of experience and understanding of the challenges faced in the global healthcare and pharmaceutical markets today.